Skip to content

Valneva

  • Über uns
    Über uns Advancing vaccines for better lives Mehr lesen
    • Unsere Strategie
    • Unsere Expertise im Bereich der Reisegesundheit
    • Unsere Verantwortung
    • Unser Team
  • Produkte
    Produkte Fokus auf Impfstoffe für Infektionskrankheiten mit hohem ungedecktem Bedarf Mehr lesen
    • Japanische Enzephalitis-Impfstoff
    • Cholera-Impfstoff
    • COVID-19 Impfstoff
    • Marketing und Vertrieb
    • Produktion und Dienstleistungen
  • F&E
    F&E Dedicated to innovation in vaccine research and development Mehr lesen
    • Pipeline
    • Lyme Borreliose – VLA15
    • Chikungunya – VLA1553
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access-Richtlinie
    • Wissenschaftliche Publikationen
  • Investoren
    Investoren Mehr lesen
    • Events und Präsentationen
      • Kalender
      • Präsentationen des Unternehmens
    • Financial & Filings
      • Finanzberichte
      • SEC Filings
    • Pressemeldungen
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Vorgeschriebene Informationen
    • Aktieninformation
      • Aktienkurs
      • Analysten
      • Aktionärsstruktur
      • Delisting von der Wiener Börse
    • Hauptversammlungen
      • 2023 Kombinierte Hauptversammlung
      • 2022 Kombinierte Hauptversammlung
      • June 23, 2022 Special Meeting
      • Archiv Hauptversammlungen
    • Videos und Webcasts
    • Häufig gestellte Fragen
    • Kontakt
  • Medien
    Medien Pressemeldungen, Aktuelles und Ressourcen für Medien Mehr lesen
    • Pressemeldungen
    • In den Nachrichten
    • Ressourcen für Medien
    • Medienkontakte
  • Karriere
Kontakt
  • EN
  • FR
  • | DE
Search

Pressemeldungen

September 23, 2008

VIVALIS SECURES AN IMPORTANT PATENT COVERING ITS EBx® PLATFORM

September 10, 2008

PARTICIPATION AT THE MIDCAP EVENT IN PARIS ON 29 AND 30 SEPTEMBER 2008

August 28, 2008

Results for the 1st half-year in line with VIVALIS targets and strategy A solid commercial dynamic: 4 new license agreements since the beginning of 2008 Enhanced financial strength and visibility with a new €6m grant from Oséo through its new strategic industrial innovation support program

August 13, 2008

VIVALIS: A very dynamic 2nd quarter for licensing Half year cash position of M€ 21.4

July 22, 2008

GeoVax Partners with VIVALIS for Use of its Revolutionary EBx® Technology to Manufacture its MVA HIV/AIDS Vaccine

July 15, 2008

VIVALIS AND INTERVET SCHERING PLOUGH ANIMAL HEALTH SIGN A LETTER OF INTENT FOR A COMMERCIAL LICENSE TO USE EBx® CELL LINE FOR A VIRAL VACCINE PRODUCTION

July 8, 2008

VIVALIS GRANTS RESEARCH LICENCE TO ACAMBIS TO EVALUATE EB66® CELL LINE FOR VIRAL VACCINES PRODUCTION

June 30, 2008

A MAJOR STEP TAKEN IN THE DEVELOPMENT OF VIVALIS: FILING OF THE EB66® CELL LINE BMF WITH THE AMERICAN FDA CONFIRMATION OF BREAKTHROUGH TECHNOLOGY STATUS FOR THE PRODUCTION OF VACCINES AND PROTEINS

June 18, 2008

VIVALIS GRANTS RIGHTS TO EBx® CELL LINE FOR TESTING IN PRODUCTION OF VIRAL VACCINES

June 3, 2008

FOLLOWING POSITIVE RESULTS VIVALIS AND BAVARIAN NORDIC EXTEND THE EBx® RESEARCH LICENCE

  • 1
  • …
  • 48
  • 49
  • 50
  • 51
  • 52

Valneva

  • Über uns
  • Produkte
  • F&E
  • Investoren
  • Medien
  • Karriere
Weitere Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Kontakt
© 2023 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
ACCEPT REJECT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policy.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website. Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website. For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you. The information collected through these tracking and performance cookies do not identify any individual visitor.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT